Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 06, 2022 23:27 ET | Source: iBio, Inc.

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its...
December 06, 2022 16:01 ET | Source: iBio, Inc.

iBio Announces Proposed Underwritten Public Offering

BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced it intends to offer...
December 06, 2022 08:00 ET | Source: iBio, Inc.

iBio to Participate in the JMP Securities Hematology and Oncology Summit

BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its Chief...
December 05, 2022 08:00 ET | Source: iBio, Inc.

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

BRYAN, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today it will present two...
December 02, 2022 16:30 ET | Source: iBio, Inc.

iBio Announces CEO Departure

BRYAN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the Board of...
November 03, 2022 08:00 ET | Source: iBio, Inc.

iBio Accelerates Transformation to AI-Powered Biotech

– Divesting CDMO business and cGMP biologics manufacturing facility – – Investing in pipeline of immuno-oncology assets and AI-based drug discovery platform – – Restructuring measures to result in...
September 27, 2022 16:10 ET | Source: iBio, Inc.

iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the...
September 21, 2022 08:30 ET | Source: iBio, Inc.

iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline

– Positions Company for leadership in AI-powered drug discovery – – Expands iBio’s immuno-oncology pipeline with three new candidates – – Hosting investor call on September 27th to discuss...
August 16, 2022 09:00 ET | Source: iBio, Inc.

iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate

- Manufactured first batch of drug substance under cGMP conditions - - Analysis of challenge study data underway - BRYAN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio”...
May 18, 2022 08:00 ET | Source: iBio, Inc.

iBio to Participate in the H.C. Wainwright Global Investment Conference

BRYAN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...